Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release 
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
 32nd Annual Meeting - EconoTimes)
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2017 -- Five Prime Therapeutics, Inc. (NASDAQ:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, previously announced that the abstract featuring data from the Phase 1a/1b clinical trial evaluating the immunotherapy combination of its CSF-1R antibody, cabiralizumab (FPA008), with Opdivo® (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, has been selected for a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting, being held Nov. 8-12, 2017 in National Harbor, Maryland.
Five Prime will host a conference call and live audio webcast on Saturday, November 11, 2017, at 5:45 p.m. (ET). Lewis T. “Rusty” Williams, President and Chief Executive Officer, Aron Knickerbocker, Chief Operating Officer, Helen Collins, Chief Medical Officer and Dr. Zev Wainberg, Assistant Professor of Medicine at UCLA, will review the data presented at SITC earlier that day.
The live audio webcast may be accessed through the "Events & Presentations" page in the "Investors" section of the company's website at www.fiveprime.com. Alternatively, participants may dial (877) 878-2269 (domestic) or (253) 237-1188 (international) and refer to conference ID 4092848.
The archived conference call will be available on Five Prime's website beginning approximately two hours after the event and will be archived and available for replay for at least 30 days after the event.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.
CONTACT:
Derek Cole
Investor Relations Advisory Solutions
720-785-4497
[email protected]
